From the Center for Drug Discovery, University of North Carolina at Greensboro, Greensboro, North Carolina 27402.
J Biol Chem. 2014 Feb 28;289(9):5828-45. doi: 10.1074/jbc.M113.478495. Epub 2013 Dec 23.
The cannabinoid 1 (CB1) allosteric modulator, 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide) (ORG27569), has the paradoxical effect of increasing the equilibrium binding of (3)H-3-[2-hydroxyl-4-(1,1-dimethylheptyl)phenyl]-4-[3-hydroxylpropyl]cyclohexan-1-ol (CP55,940, an orthosteric agonist) while at the same time decreasing its efficacy (in G protein-mediated signaling). ORG27569 also decreases basal signaling, acting as an inverse agonist for the G protein-mediated signaling pathway. In ligand displacement assays, ORG27569 can displace the CB1 antagonist/inverse agonist, N-(piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide(SR141716A). The goal of this work was to identify the binding site of ORG27569 at CB1. To this end, we used computation, synthesis, mutation, and functional studies to identify the ORG27569-binding site in the CB1 TMH3-6-7 region. This site is consistent with the results of K3.28(192)A, F3.36(200)A, W5.43(279)A, W6.48(356)A, and F3.25(189)A mutation studies, which revealed the ORG27569-binding site overlaps with our previously determined binding site of SR141716A but extends extracellularly. Additionally, we identified a key electrostatic interaction between the ORG27569 piperidine ring nitrogen and K3.28(192) that is important for ORG27569 to act as an inverse agonist. At this allosteric site, ORG27569 promotes an intermediate conformation of the CB1 receptor, explaining ORG27569's ability to increase equilibrium binding of CP55,940. This site also explains ORG27569's ability to antagonize the efficacy of CP55,940 in three complementary ways. 1) ORG27569 sterically blocks movements of the second extracellular loop that have been linked to receptor activation. 2) ORG27569 sterically blocks a key electrostatic interaction between the third extracellular loop residue Lys-373 and D2.63(176). 3) ORG27569 packs against TMH6, sterically hindering movements of this helix that have been shown to be important for receptor activation.
大麻素 1 型(CB1)别构调节剂,5-氯-3-乙基-1H-吲哚-2-羧酸[2-(4-哌啶-1-基-苯基)-乙基]-酰胺](ORG27569)具有增加平衡结合的矛盾作用[(3)H](-)-3-[2-羟基-4-(1,1-二甲基庚基)苯基]-4-[3-羟基丙基]环己烷-1-醇(CP55,940,一个正位激动剂),同时降低其功效(在 G 蛋白介导的信号转导中)。ORG27569 还降低基础信号,作为 G 蛋白介导的信号通路的反向激动剂。在配体置换测定中,ORG27569 可以置换 CB1 拮抗剂/反向激动剂,N-(哌啶基-1-基)-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-羧酰胺(SR141716A)。这项工作的目的是确定 ORG27569 在 CB1 中的结合位点。为此,我们使用计算、合成、突变和功能研究来确定 CB1 TMH3-6-7 区域中 ORG27569 的结合位点。该位点与 K3.28(192)A、F3.36(200)A、W5.43(279)A、W6.48(356)A 和 F3.25(189)突变研究的结果一致,这些研究表明 ORG27569 的结合位点与我们先前确定的 SR141716A 的结合位点重叠,但向细胞外延伸。此外,我们还确定了 ORG27569 哌啶环氮与 K3.28(192)之间的关键静电相互作用,这对于 ORG27569 作为反向激动剂很重要。在这个别构位点,ORG27569 促进 CB1 受体的中间构象,解释了 ORG27569 增加 CP55,940 平衡结合的能力。该位点还解释了 ORG27569 以三种互补方式拮抗 CP55,940 功效的能力。1)ORG27569 空间上阻止与受体激活相关的第二细胞外环的运动。2)ORG27569 空间上阻止第三细胞外环残基赖氨酸 373 和 D2.63(176)之间的关键静电相互作用。3)ORG27569 与 TMH6 结合,阻碍该螺旋的运动,该螺旋的运动已被证明对受体激活很重要。